Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Alzheimer's Disease

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 98 articles:
HTML format



Single Articles


    March 2024
  1. LACHNER C, Craver EC, Babulal GM, Lucas JA, et al
    Disparate Dementia Risk Factors Are Associated with Cognitive Impairment and Rates of Decline in African Americans.
    Ann Neurol. 2024;95:518-529.
    PubMed     Abstract available


  2. PAPP KV, Jutten RJ, Soberanes D, Weizenbaum E, et al
    Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.
    Ann Neurol. 2024;95:507-517.
    PubMed     Abstract available


    February 2024
  3. VAN EGROO M, van Someren EJW, Grinberg LT, Bennett DA, et al
    Associations of 24-Hour Rest-Activity Rhythm Fragmentation, Cognitive Decline, and Postmortem Locus Coeruleus Hypopigmentation in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 26. doi: 10.1002/ana.26880.
    PubMed     Abstract available


  4. LI Y, Yen D, Hendrix RD, Gordon BA, et al
    Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26891.
    PubMed     Abstract available


  5. PHAN TX, Baratono S, Drew W, Tetreault AM, et al
    Increased Cortical Thickness in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26894.
    PubMed     Abstract available


  6. SALTIEL N, Tripodis Y, Menzin T, Olaniyan A, et al
    Relative Contributions of Mixed Pathologies to Cognitive and Functional Symptoms in Brain Donors Exposed to Repetitive Head Impacts.
    Ann Neurol. 2024;95:314-324.
    PubMed     Abstract available


  7. KUCHENBECKER LA, Tipton PW, Martens Y, Brier MR, et al
    Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.
    Ann Neurol. 2024;95:299-313.
    PubMed     Abstract available


  8. CHEN X, Toueg TN, Harrison TM, Baker SL, et al
    Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
    Ann Neurol. 2024;95:249-259.
    PubMed     Abstract available


    January 2024
  9. VANCE JM, Farrer LA, Huang Y, Cruchaga C, et al
    Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease.
    Ann Neurol. 2024 Jan 5. doi: 10.1002/ana.26864.
    PubMed     Abstract available


    December 2023
  10. BONOMI S, Lu R, Schindler SE, Bui Q, et al
    Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
    Ann Neurol. 2023 Dec 1. doi: 10.1002/ana.26838.
    PubMed     Abstract available


    October 2023
  11. ZHENG L, Rubinski A, Dennecke J, Luan Y, et al
    Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer's Disease.
    Ann Neurol. 2023 Oct 14. doi: 10.1002/ana.26818.
    PubMed     Abstract available


  12. GRILL JD, Flournoy C, Dhadda S, Ernstrom K, et al
    Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease.
    Ann Neurol. 2023 Oct 13. doi: 10.1002/ana.26819.
    PubMed     Abstract available


  13. DARK HE, Paterson C, Daya GN, Peng Z, et al
    Proteomic indicators of health predict Alzheimer's disease biomarker levels and dementia risk.
    Ann Neurol. 2023 Oct 6. doi: 10.1002/ana.26817.
    PubMed     Abstract available


  14. SHAW LM, Galasko D
    Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD.
    Ann Neurol. 2023;94:618-619.
    PubMed    


  15. SOLDAN A, Oh S, Ryu T, Pettigrew C, et al
    NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.
    Ann Neurol. 2023;94:620-631.
    PubMed     Abstract available


    September 2023
  16. HIRATA K, Matsuoka K, Tagai K, Endo H, et al
    Altered brain energy metabolism related to astrocytes in Alzheimer's disease.
    Ann Neurol. 2023 Sep 13. doi: 10.1002/ana.26797.
    PubMed     Abstract available


    August 2023
  17. MINOGUE G, Kawles A, Zouridakis A, Keszycki R, et al
    Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with TDP-43.
    Ann Neurol. 2023 Aug 18. doi: 10.1002/ana.26762.
    PubMed     Abstract available


  18. KOSIK KS
    Search Strategies for Alzheimer Protector Genes.
    Ann Neurol. 2023 Aug 13. doi: 10.1002/ana.26764.
    PubMed     Abstract available


  19. YU L, Petyuk VA, Lopes KP, Tasaki S, et al
    Associations of VGF with Neuropathologies and Cognitive Health in Older Adults.
    Ann Neurol. 2023;94:232-244.
    PubMed     Abstract available


  20. CHEN XQ, Sawa M, Becker A, Karachentsev D, et al
    Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a gamma-Secretase Modulator.
    Ann Neurol. 2023;94:245-258.
    PubMed     Abstract available


    July 2023
  21. KUHLENBAUMER G, Jensen-Kondering U, Margraf NG
    Decreased Cerebrospinal Fluid Amyloid Beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;94:205.
    PubMed    


  22. LUCEY BP, Liu H, Toedebusch CD, Freund D, et al
    Suvorexant Acutely Decreases Tau Phosphorylation and Abeta in the Human CNS.
    Ann Neurol. 2023;94:27-40.
    PubMed     Abstract available


    June 2023
  23. LUCEY BP, Bateman RJ
    Reply to Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 28. doi: 10.1002/ana.26728.
    PubMed    


  24. KAWADA T
    Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26733.
    PubMed    


  25. DE KORT AM, Kuiperij HB, Marques TM, Jakel L, et al
    Decreased Cerebrospinal Fluid Amyloid beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;93:1173-1186.
    PubMed     Abstract available


    May 2023
  26. NELSON PT, Schneider JA, Jicha GA, Duong MT, et al
    When Alzheimer's is LATE: Why does it matter?
    Ann Neurol. 2023 May 28. doi: 10.1002/ana.26711.
    PubMed     Abstract available


  27. HOOSHMAND B, Appold F, Fissler P, Perneczky R, et al
    Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers of Alzheimer's disease and cognitive performance.
    Ann Neurol. 2023 May 12. doi: 10.1002/ana.26673.
    PubMed     Abstract available


  28. ANDRE C, Champetier P, Rehel S, Kuhn E, et al
    Rapid Eye Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging.
    Ann Neurol. 2023;93:979-990.
    PubMed     Abstract available


    April 2023
  29. NEDELEC T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, et al
    A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
    Ann Neurol. 2023 Apr 25. doi: 10.1002/ana.26670.
    PubMed     Abstract available


  30. SHAHID M, Rawls A, Ramirez V, Ryman S, et al
    Illusory Responses across the Lewy Body Disease Spectrum.
    Ann Neurol. 2023;93:702-714.
    PubMed     Abstract available


    March 2023
  31. MUSIEK ES, McDade E, Holtzman DM
    Lecanamab ushers in a new era of anti-amyloid therapy for Alzheimer's Disease.
    Ann Neurol. 2023 Mar 15. doi: 10.1002/ana.26643.
    PubMed    


  32. PYUN JM, Park YH, Wang J, Bice PJ, et al
    Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26637.
    PubMed    


  33. LAN G, Guo T
    Reply to: "Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific".
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26639.
    PubMed    


  34. TROPEA TF, Albuja I, Cousins KAQ, Irwin DJ, et al
    Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia.
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26635.
    PubMed    


  35. YOUNCE JR, Martin WRW, Perlmutter JS
    Reply to "Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia".
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26630.
    PubMed    


    February 2023
  36. HORIE K, Li Y, Barthelemy NR, Gordon BA, et al
    Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in Dominantly Inherited Alzheimer's Disease.
    Ann Neurol. 2023 Feb 26. doi: 10.1002/ana.26620.
    PubMed     Abstract available


    December 2022
  37. RUBINSKI A, Frerich S, Malik R, Franzmeier N, et al
    Polygenic effect on tau pathology progression in Alzheimer's disease.
    Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26588.
    PubMed     Abstract available


  38. BEASON-HELD LL, Kerley CI, Chaganti S, Moghekar A, et al
    Health Conditions Associated with Alzheimer's Disease and Vascular Dementia.
    Ann Neurol. 2022 Dec 26. doi: 10.1002/ana.26584.
    PubMed     Abstract available


  39. MENESES AD, Koga S, Li Z, O'Leary J, et al
    APOE2 Exacerbates TDP-43 Related Toxicity in the Absence of Alzheimer Pathology.
    Ann Neurol. 2022 Dec 22. doi: 10.1002/ana.26580.
    PubMed     Abstract available


  40. BRENOWITZ WD, Fornage M, Launer LJ, Habes M, et al
    Alzheimer's disease genetic risk, cognition, and brain aging in midlife.
    Ann Neurol. 2022 Dec 13. doi: 10.1002/ana.26569.
    PubMed     Abstract available


  41. LAHNA D, Schwartz DL, Woltjer R, Black SE, et al
    Venous Collagenosis as Pathogenesis of White Matter Hyperintensity.
    Ann Neurol. 2022;92:992-1000.
    PubMed     Abstract available


    November 2022
  42. MARTIN WRW, Younce JR, Campbell MC, Racette BA, et al
    Neocortical Lewy body pathology parallels Parkinson's dementia, but not always.
    Ann Neurol. 2022 Nov 4. doi: 10.1002/ana.26542.
    PubMed     Abstract available


  43. YAU WW, Shirzadi Z, Yang HS, Ikoba AP, et al
    Tau Mediates Synergistic Influence of Vascular Risk and Abeta on Cognitive Decline.
    Ann Neurol. 2022;92:745-755.
    PubMed     Abstract available


  44. COUSINS KAQ, Shaw LM, Shellikeri S, Dratch L, et al
    Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis.
    Ann Neurol. 2022;92:807-818.
    PubMed     Abstract available


    October 2022
  45. HSU JL, Wei YC, Toh CH, Hsiao IT, et al
    MRI images implicate glymphatic alterations mediate cognitive dysfunction in AD.
    Ann Neurol. 2022 Oct 10. doi: 10.1002/ana.26516.
    PubMed     Abstract available


  46. GOTTESMAN RF, Wu A, Coresh J, Knopman DS, et al
    Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia.
    Ann Neurol. 2022;92:607-619.
    PubMed     Abstract available


    September 2022
  47. JOSEPH-MATHURIN N, Llibre-Guerra JJ, Li Y, McCullough AA, et al
    Amyloid-related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease.
    Ann Neurol. 2022 Sep 24. doi: 10.1002/ana.26511.
    PubMed     Abstract available


  48. CASULA EP, Borghi I, Maiella M, Pellicciari MC, et al
    Regional precuneus cortical hyperexcitability in Alzheimer's disease patients.
    Ann Neurol. 2022 Sep 22. doi: 10.1002/ana.26514.
    PubMed     Abstract available


  49. JOH HK, Kwon H, Son KY, Yun JM, et al
    Allergic diseases and risk of incident dementia and Alzheimer's disease.
    Ann Neurol. 2022 Sep 12. doi: 10.1002/ana.26506.
    PubMed     Abstract available


  50. LAN G, Cai Y, Li A, Liu Z, et al
    Association of presynaptic loss with Alzheimer's disease and cognitive decline.
    Ann Neurol. 2022 Sep 3. doi: 10.1002/ana.26492.
    PubMed     Abstract available


  51. HU H, Bi YL, Shen XN, Ma YH, et al
    Application of the Amyloid/Tau/Neurodegeneration Framework in Cognitively Intact Adults: The CABLE Study.
    Ann Neurol. 2022;92:439-450.
    PubMed     Abstract available


  52. SMIRNOV DS, Salmon DP, Galasko D, Edland SD, et al
    TDP-43 Pathology Exacerbates Cognitive Decline in Primary Age-Related Tauopathy.
    Ann Neurol. 2022;92:425-438.
    PubMed     Abstract available


  53. BACHMANN D, Roman ZJ, Buchmann A, Zuber I, et al
    Lifestyle Affects Amyloid Burden and Cognition Differently in Men and Women.
    Ann Neurol. 2022;92:451-463.
    PubMed     Abstract available


    August 2022
  54. AL-MUBARAK B, Ahmed Nour M, Schumacher-Schuh A, Bandres-Ciga S, et al
    Globalizing research towards diverse representation in Alzheimer's and Parkinson's disease.
    Ann Neurol. 2022 Aug 24. doi: 10.1002/ana.26483.
    PubMed    


  55. JOSEPHS KA, Tosakulwong N, Gatto RG, Weigand SD, et al
    Optimum Differentiation of Frontotemporal Lobar Degeneration from Alzheimer Disease Achieved with Cross-Sectional Tau Positron Emission Tomography.
    Ann Neurol. 2022 Aug 15. doi: 10.1002/ana.26479.
    PubMed     Abstract available


  56. RAUCHMANN BS, Brendel M, Franzmeier N, Trappmann L, et al
    Microglial Activation and Connectivity in Alzheimer Disease and Aging.
    Ann Neurol. 2022 Aug 1. doi: 10.1002/ana.26465.
    PubMed     Abstract available


    July 2022
  57. SUN L, Guo D, Jia Y, Shi M, et al
    Association Between Human Blood Metabolome and the Risk of Alzheimer's Disease.
    Ann Neurol. 2022 Jul 28. doi: 10.1002/ana.26464.
    PubMed     Abstract available


  58. HEAD E, Zetterberg H
    Commentary on Oeckl et al., "Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181".
    Ann Neurol. 2022;92:3-5.
    PubMed    


  59. OECKL P, Wagemann O, Halbgebauer S, Anderl-Straub S, et al
    Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181.
    Ann Neurol. 2022;92:6-10.
    PubMed     Abstract available


    June 2022
  60. CASULA EP, Pellicciari MC, Bonni S, Borghi I, et al
    Decreased frontal gamma activity in Alzheimer's disease patients.
    Ann Neurol. 2022 Jun 17. doi: 10.1002/ana.26444.
    PubMed     Abstract available


  61. SCHINDLER SE, Ney DE, Goss AL, Rabinovici G, et al
    ANA Investigates: The Future of Biomarkers in Alzheimer Disease.
    Ann Neurol. 2022 Jun 11. doi: 10.1002/ana.26437.
    PubMed    


  62. CORNELIS MC, Bennett DA, Weintraub S, Schneider JA, et al
    Caffeine Consumption and Dementia: Are Lewy Bodies the Link?
    Ann Neurol. 2022;91:834-846.
    PubMed     Abstract available


  63. GRATUZE M, Jiang H, Wang C, Xiong M, et al
    APOE Antibody Inhibits Abeta-Associated Tau Seeding and Spreading in a Mouse Model.
    Ann Neurol. 2022;91:847-852.
    PubMed     Abstract available


    May 2022
  64. BENUSSI A, Cantoni V, Grassi M, Brechet L, et al
    Increasing brain gamma activity improves episodic memory and restores cholinergic dysfunction in Alzheimer's disease.
    Ann Neurol. 2022 May 24. doi: 10.1002/ana.26411.
    PubMed     Abstract available


  65. GANDY S
    A Letter Concerning "Aducanumab: What about the Patient?"
    Ann Neurol. 2022;91:732-733.
    PubMed    


    April 2022
  66. BUCKLEY RF, O'Donnell A, McGrath ER, Jacobs HIL, et al
    Menopause status moderates sex differences in tau burden: a Framingham PET Study.
    Ann Neurol. 2022 Apr 26. doi: 10.1002/ana.26382.
    PubMed     Abstract available


    March 2022
  67. LEE YG, Jeon S, Park M, Kang SW, et al
    Effects of Alzheimer's and Lewy Body Disease Pathologies on Brain Metabolism.
    Ann Neurol. 2022 Mar 21. doi: 10.1002/ana.26355.
    PubMed     Abstract available


  68. BENITEZ A, Jensen JH, Thorn K, Dhiman S, et al
    Greater diffusion restriction in white matter in Preclinical Alzheimer's disease.
    Ann Neurol. 2022 Mar 13. doi: 10.1002/ana.26353.
    PubMed     Abstract available


    January 2022
  69. MEYER PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, et al
    Plasma p-tau231, p-tau181, PET biomarkers and cognitive change in older adults.
    Ann Neurol. 2022 Jan 27. doi: 10.1002/ana.26308.
    PubMed     Abstract available


    October 2021
  70. SANDROCK A
    Letter Concerning Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease by Moghavem, Henderson, and Greicius.
    Ann Neurol. 2021 Oct 23. doi: 10.1002/ana.26254.
    PubMed    


  71. DAS SR, Lyu X, Duong MT, Xie L, et al
    Tau-atrophy variability reveals phenotypic heterogeneity in Alzheimer's disease.
    Ann Neurol. 2021 Oct 7. doi: 10.1002/ana.26233.
    PubMed     Abstract available


    September 2021
  72. PETERSEN RC
    Aducanumab: What about the Patient?
    Ann Neurol. 2021;90:334-335.
    PubMed    


    July 2021
  73. TAN EK
    Genetic studies of Parkinson's & Alzheimer's disease in Latinos/Hispanics: New Insights & Challenges.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26179.
    PubMed    


  74. MONTAL V, Barroeta I, Bejanin A, Pegueroles J, et al
    Metabolite signature of Alzheimer's disease in adults with Down syndrome.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26178.
    PubMed     Abstract available


  75. DAUTRICOURT S, de Flores R, Landeau B, Poisnel G, et al
    Longitudinal changes in hippocampal network connectivity in Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26168.
    PubMed     Abstract available


  76. MOGHAVEM N, Henderson VW, Greicius MD
    Medicare should not cover aducanumab as a treatment for Alzheimer's disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26167.
    PubMed    


    May 2021
  77. LIN BSZ, Sur S, Liu P, Li Y, et al
    Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26134.
    PubMed     Abstract available


  78. SARIYA S, Felsky D, Reyes-Dumeyer D, Lali R, et al
    Polygenic risk score for Alzheimer's Disease in Caribbean Hispanics.
    Ann Neurol. 2021 May 26. doi: 10.1002/ana.26131.
    PubMed     Abstract available


    April 2021
  79. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    PubMed     Abstract available


    March 2021
  80. PETERSEN RC, Wiste HJ, Weigand SD, Fields JA, et al
    NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26071.
    PubMed     Abstract available


  81. BUCIUC M, Whitwell JL, Kasanuki K, Graff-Radford J, et al
    Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype.
    Ann Neurol. 2021;89:520-533.
    PubMed     Abstract available


    February 2021
  82. KONIJNENBERG E, Tomassen J, den Braber A, Ten Kate M, et al
    The onset of preclinical Alzheimer's disease in monozygotic twins.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26048.
    PubMed     Abstract available


  83. FILIPPONE A, Pratico D
    Endosome dysregulation in Down syndrome: a potential contributor to Alzheimer's disease pathology.
    Ann Neurol. 2021 Feb 6. doi: 10.1002/ana.26042.
    PubMed     Abstract available


  84. MEEKER KL, Wisch JK, Hudson D, Coble D, et al
    Socioeconomic Status Mediates Racial Differences Seen Using the AT(N) Framework.
    Ann Neurol. 2021;89:254-265.
    PubMed     Abstract available


    December 2020
  85. RAJAN KB, Aggarwal NT, McAninch EA, Weuve J, et al
    Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study.
    Ann Neurol. 2020;88:1065-1076.
    PubMed     Abstract available


    November 2020
  86. LESMAN-SEGEV OH, La Joie R, Iaccarino L, Lobach I, et al
    Diagnostic Accuracy of Amyloid versus FDG PET in Autopsy-Confirmed Dementia.
    Ann Neurol. 2020 Nov 20. doi: 10.1002/ana.25968.
    PubMed     Abstract available


  87. BUCKLEY RF, Scott MR, Jacobs HIL, Schultz AP, et al
    Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline.
    Ann Neurol. 2020;88:921-932.
    PubMed     Abstract available


    October 2020
  88. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25947.
    PubMed    


  89. MOUSSA C
    Reply to Cardiovascular Safety of Nilotinib in Alzheimer's Disease.
    Ann Neurol. 2020 Oct 25. doi: 10.1002/ana.25946.
    PubMed    


  90. NOYCE AJ, Klein C
    Genetic risk of Alzheimer's disease - Sleepless with the enemy.
    Ann Neurol. 2020 Oct 18. doi: 10.1002/ana.25938.
    PubMed    


  91. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    PubMed     Abstract available


    September 2020
  92. ANDREWS SJ, Fulton-Howard B, O'Reilly P, Marcora E, et al
    Causal associations between modifiable risk factors and the Alzheimer's phenome.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25918.
    PubMed     Abstract available


    August 2020
  93. GHIRELLI A, Tosakulwong N, Weigand SD, Clark HM, et al
    Sensitivity-specificity of tau and Abeta PET in frontotemporal lobar degeneration.
    Ann Neurol. 2020 Aug 31. doi: 10.1002/ana.25893.
    PubMed     Abstract available


    July 2020
  94. NUNEZ C, Callen A, Lombardini F, Compta Y, et al
    Different Cortical Gyrification Patterns in Alzheimer's Disease and Impact on Memory Performance.
    Ann Neurol. 2020;88:67-80.
    PubMed     Abstract available


    June 2020
  95. SCARIONI M, Gami-Patel P, Timar Y, Seelaar H, et al
    Frontotemporal Dementia: Correlations Between Psychiatric Symptoms and Pathology.
    Ann Neurol. 2020;87:950-961.
    PubMed     Abstract available


  96. BUCKLEY R, Pascual-Leone A
    Age-Related Cognitive Decline Is Indicative of Neuropathology.
    Ann Neurol. 2020;87:813-815.
    PubMed    


    May 2020
  97. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    PubMed    


    April 2020
  98. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.